BOPI 08 BR/2023 REPERTOIRE NUMERIQUE 18 Consulter le mémoire ________________________________________ (11) 21090 (51) A61K 31/19 (2018.01); A61K 9/107 (2018.01) ; B82Y 5/00 (2018.01) (21) 1202200050 - PCT/MX2020/050025 (22) 07/08/2020 (30) MX n° MX/a/2019/009482 du 08/08/2019 (54) Nanoemulsion of 18β-Glycyrrhetinic acid. (72) ZENDEJAS HERNANDEZ, Ulises (MX) (73) ATSO CORPORATE AFFAIRS, S.A. DE C.V, Meseta No. 232, Col. Jardines del Pedregal, MEXICO CITY 01900 (MX) (74) SPOOR & FISHER Inc. NGWAFOR & PARTNERS SARL, The House of Gideon, Golf/Bastos Quarter, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, B.P. 8211, YAOUNDE (CM). (57) The invention refers to pharmaceutical forms that potentiate the bioavailability of 18β-GA, having a high permeation on the application area mainly due to the effect of their small particle size, high concentration of the active ingredient, excipient composition, micelles with specific structural composition and polarity. The present pharmaceutical forms exhibit specific values for particle size, permeability, diffusion coefficient, and polydispersity helping to provide its technical advantages. Therapeutic uses of the pharmaceutical forms are also described, which include those therapeutic uses for which 1 8βglycyrrhetinic acid is known to have an effect, such as anti-inflammatory, antiviral, antibacterial activity, hepatoprotective, used against skin diseases and anticarcinogenic. Mainly gelled solutions, emulsions and nanoemulsions, are intended for application in the vaginal and cervical area, for the treatment of diseases related to the human papillomavirus, such as infections, lesions, and cervical cancer. Fig. 2 A & 2 B Consulter le mémoire ________________________________________ (11) 21091 (51) F16L 15/04 (2018.01) (21) 1202200056 - PCT/JP2020/031453 (22) 20/08/2020 (30) JP n° 2019-172936 du 24/09/2019
RkJQdWJsaXNoZXIy MTM1NDc3MA==